High levels of latent antithrombin in plasma from patients with antithrombin deficiency

Thromb Haemost. 2017 May 3;117(5):880-888. doi: 10.1160/TH16-11-0866. Epub 2017 Feb 23.

Abstract

Antithrombin is an anticoagulant serpin that efficiently inhibits multiple procoagulant proteases. The cost for the structural flexibility required for this function is the vulnerability to mutations that impact its folding pathway. Most conformational mutations identified in serpins cause polymerisation. Only three mutations in SERPINC1 affecting two residues have been found to favour transformation to the latent conformation of antithrombin, another hyperstable non-anticoagulant form with strong antiangiogenic activity that constitutes 3 % of plasma antithrombin in healthy subjects. The analysis of latent antithrombin in 141 unrelated patients with antithrombin deficiency carrying 89 different SERPINC1 mutations identified four cases with higher levels than that of controls: p.Pro439Thr, p.Pro461Ser, p.Met283Val, and p.His401Tyr, the last also with circulating polymers. Heating of plasma at 42ºC exacerbated the transformation to the latent conformation in p.Pro439Thr and p.Pro461Ser. The conformational effect of p.Met283Val, the mutation associated with the highest levels of latent antithrombin detected in four members of a family, was verified in a recombinant model. Antithrombin deficiency in these cases should be classified as pleiotropic based on the impaired reactivity and low heparin affinity of the variant. Despite high levels of latent antithrombin (up to 80 µg/ml in p.Met283Val carriers), no vascular defects were described in carriers of these mutations. In conclusion, our study identifies new residues involved in the structural stability of antithrombin (and potentially of all serpins). High levels of endogenous latent antithrombin seem to play a minor antiangiogenic effect. Finally, pleiotropic deficiencies may be caused by mutations inducing transformation to the latent conformation.

Keywords: Antithrombin; gene mutations; latent; thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antithrombin III / analysis*
  • Antithrombin III / chemistry
  • Antithrombin III / genetics
  • Antithrombin III Deficiency / blood*
  • Antithrombin III Deficiency / diagnosis
  • Antithrombin III Deficiency / genetics
  • Biomarkers / blood
  • Blood Coagulation* / genetics
  • Case-Control Studies
  • Child
  • DNA Mutational Analysis
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Infant, Newborn
  • Male
  • Middle Aged
  • Models, Molecular
  • Mutation
  • Phenotype
  • Protein Conformation
  • Protein Stability
  • Structure-Activity Relationship
  • Temperature
  • Up-Regulation
  • Venous Thrombosis / blood*
  • Venous Thrombosis / diagnosis
  • Venous Thrombosis / genetics

Substances

  • Biomarkers
  • SERPINC1 protein, human
  • Antithrombin III